久久一区二区三区四区_欧美高清dvd_日韩欧美在线看_国产精品欧美一区二区_av天天看_欧美精品免费观看二区

微創(chuàng)醫(yī)療  MicroPort  
微創(chuàng)醫(yī)療器械（上海）有限公司， 由留美科學(xué)家常兆華博士創(chuàng)辦于一九九八年五月，現(xiàn)已成為由Otsuka Pharmaceutical Corporation （大冢制藥株式會社）、We'Tron Capital China Limited （中國微創(chuàng)投資管理有限公司）、SIIC MedTech Health Products Limited （上實醫(yī)藥健康產(chǎn)品有限公司）等投資的外商合資企業(yè)，主要從事各種高科技微創(chuàng)傷介入醫(yī)療產(chǎn)品的研究、制造、銷售和服務(wù)，公司被認定為上海市高新技術(shù)企業(yè)。

公司的宗旨是“以人為本，在微創(chuàng)傷介入醫(yī)學(xué)領(lǐng)域建設(shè)屬于中華民族的世界級醫(yī)療集團”。公司研發(fā)中心被認定為上海市技術(shù)研發(fā)中心，吸納了美國多位著名的生物醫(yī)學(xué)工程界專家和介入醫(yī)療界科學(xué)家，擁有數(shù)十名包括博士、碩士在內(nèi)的微創(chuàng)傷介入醫(yī)療器材產(chǎn)品開發(fā)與生產(chǎn)方面的專業(yè)人才，擁有藥物支架包裹技術(shù)、顱內(nèi)支架等數(shù)十項技術(shù)專利和多項獨立知識產(chǎn)權(quán)，目前，正開發(fā)多種高科技微創(chuàng)傷介入治療產(chǎn)品，并多個項目獲國家、上海市、浦東新區(qū)多項科技基金的資助。

公司主要產(chǎn)品有冠脈藥物支架系統(tǒng)、冠脈金屬支架系統(tǒng)、顱內(nèi)動脈支架系統(tǒng)、腹主動脈瘤和胸主動脈瘤等支撐型人造血管支架、球囊 (PTCA)擴張導(dǎo)管、導(dǎo)引導(dǎo)管及其相關(guān)附件、胰島素泵、 射頻消融電生理導(dǎo)管等醫(yī)療器械；它們中絕大多數(shù)填補國內(nèi)空白，被認定為上海市高新技術(shù)成果轉(zhuǎn)化項目，達國際先進水平，直接與國外產(chǎn)品競爭，已進入中國各大知名醫(yī)院，并出口日本、歐洲、拉美等國家與地區(qū)，具有一定的品牌知名度和市場占有率。

公司始終以創(chuàng)建“一個屬于醫(yī)生和病人的品牌”為已任，高舉民族工業(yè)的大旗，誠懇地希望與國內(nèi)外各界人士精誠合作，共同努力，力爭將公司發(fā)展成為我國介入醫(yī)療器械的主要生產(chǎn)基地和科研開發(fā)中心。
   

The Leading Chinese Developer of Interventional Medical Products

MicroPort is the leading Chinese developer, manufacturer, and marketer of innovative medical products for interventional cardiology and peripheral vascular diseases.

Since 1998, we assembled some of the very best talent in the medical device industry and set forth on a mission to develop superior medical technology for the interventional cardiology market. We were also determined to create affordable devices so that they would be accessible to people throughout China and emerging markets around the world.

Our initial success served as a foundation from which we are pioneering an expansive set of medical technologies. Under the leadership of a management team with extensive multinational medical experience, MicroPort is growing rapidly within and beyond our domestic region.

We are extending our solutions to Europe, Latin America, South America and other emerging markets. And we are working closely with physicians, hospitals, key opinion leaders, and government regulatory agencies to extend our technology throughout the world.

We represent the most extensive medical products company in one of the world’s largest countries. Our solid platform – including powerful R&D, vertically integrated manufacturing and worldwide distribution – is readily leveraged for new technologies and new markets. As we replicate our success in other regions, we are destined to become the first China-based, multinational medical product leader, bringing affordable products to people across the globe.